Squarepoint Ops LLC acquired a new position in shares of Nautilus Biotechnology, Inc. (NASDAQ:NAUT – Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 26,324 shares of the company’s stock, valued at approximately $44,000. Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Virtu Financial LLC bought a new position in Nautilus Biotechnology during the fourth quarter worth about $28,000. Cubist Systematic Strategies LLC bought a new position in Nautilus Biotechnology during the fourth quarter worth about $34,000. SG Americas Securities LLC boosted its position in Nautilus Biotechnology by 56.3% during the fourth quarter. SG Americas Securities LLC now owns 27,483 shares of the company’s stock worth $46,000 after purchasing an additional 9,904 shares during the period. Palumbo Wealth Management LLC boosted its position in shares of Nautilus Biotechnology by 45.4% in the fourth quarter. Palumbo Wealth Management LLC now owns 28,475 shares of the company’s stock valued at $48,000 after acquiring an additional 8,888 shares during the period. Finally, Millennium Management LLC bought a new position in shares of Nautilus Biotechnology in the fourth quarter valued at approximately $63,000. Institutional investors own 50.71% of the company’s stock. Nautilus Biotechnology Stock Down 2.7% Shares of NASDAQ NAUT opened at $0.75 on Wednesday. Nautilus Biotechnology, Inc. has a 52 week low of $0.66 and a 52 week high of $3.09. The company has a market cap of $94.74 million, a price-to-earnings ratio of -1.34 and a beta of 1.43. The firm’s fifty day moving average is $0.75 and its 200 day moving average is $1.32. Nautilus Biotechnology (NASDAQ:NAUT – Get Free Report) last announced its earnings results on Tuesday, April 29th. The company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.01. Equities research analysts anticipate that Nautilus Biotechnology, Inc. will post -0.57 earnings per share for the current year. Insider Activity at Nautilus Biotechnology In other Nautilus Biotechnology news, CEO Sujal M. Patel purchased 53,300 shares of the company’s stock in a transaction on Wednesday, March 19th. The stock was acquired at an average cost of $0.99 per share, for a total transaction of $52,767.00. Following the purchase, the chief executive officer now directly owns 10,117,788 shares of the company’s stock, valued at $10,016,610.12. This trade represents a 0.53% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In the last ninety days, insiders purchased 81,800 shares of company stock worth $74,172. 41.10% of the stock is owned by company insiders. Wall Street Analyst Weigh In Separately, Guggenheim set a $2.50 price objective on shares of Nautilus Biotechnology in a research report on Friday, February 28th. Get Our Latest Stock Analysis on NAUT Nautilus Biotechnology Company Profile (Free Report) Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. Read More Five stocks we like better than Nautilus Biotechnology What is the Euro STOXX 50 Index? AppLovin Dips on S&P 500 Snub, Morgan Stanley Lifts Target Anyway What Does Downgrade Mean in Investing? Casey’s Surges on Strong Q4, More Gains Likely Ahead What does consumer price index measure? Government Mandate Sends eVTOL Stocks Flying
